Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:36 AM
Ignite Modification Date:
2025-12-25 @ 4:36 AM
NCT ID:
NCT06176118
Eligibility Criteria:
Inclusion Criteria:
* Adults aged 18 or older
* Diagnosed with idiopathic, heritable, simple congenital heart defect, or drug- or toxin-associated pulmonary arterial hypertension (PAH) according to World Health Organization consensus recommendations.
* Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.
* FEV1\> or = 60% predicted and no more than mild abnormalities on lung imaging
* WHO Functional Class II-IV
* Ambulatory
Exclusion Criteria:
* Sensitivity to 2-HOBA
* Sensitivity to aspirin or salicylates
* Aspirin-related rhinitis or wheezing
* Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity
* Pregnancy
* Diagnosis of PAH etiology other than idiopathic, heritable, simple congenital heart defect, or associated with drugs or toxins
* Drug and toxin associated PAH patients with active drug use
* Prior diagnosis of cirrhosis
* Malignancy
* eGFR by MDRD \<60mL/min
* Non-english speaking
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06176118
Study Brief:
Protocol Section:
NCT06176118